JP2012021007A5 - - Google Patents

Download PDF

Info

Publication number
JP2012021007A5
JP2012021007A5 JP2011178873A JP2011178873A JP2012021007A5 JP 2012021007 A5 JP2012021007 A5 JP 2012021007A5 JP 2011178873 A JP2011178873 A JP 2011178873A JP 2011178873 A JP2011178873 A JP 2011178873A JP 2012021007 A5 JP2012021007 A5 JP 2012021007A5
Authority
JP
Japan
Prior art keywords
factor vii
composition
vii polypeptides
nanofilter
nanofiltration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011178873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012021007A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2012021007A publication Critical patent/JP2012021007A/ja
Publication of JP2012021007A5 publication Critical patent/JP2012021007A5/ja
Withdrawn legal-status Critical Current

Links

JP2011178873A 2003-12-01 2011-08-18 液体因子ｖｉｉ組成物のウイルス濾過 Withdrawn JP2012021007A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200301775 2003-12-01
DKPA200301775 2003-12-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2006541943A Division JP4874806B2 (ja) 2003-12-01 2004-12-01 液体因子ｖｉｉ組成物のウイルス濾過

Publications (2)

Publication Number Publication Date
JP2012021007A JP2012021007A (ja) 2012-02-02
JP2012021007A5 true JP2012021007A5 (https=) 2012-11-22

Family

ID=34639198

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2006541943A Expired - Lifetime JP4874806B2 (ja) 2003-12-01 2004-12-01 液体因子ｖｉｉ組成物のウイルス濾過
JP2011069695A Expired - Lifetime JP5666359B2 (ja) 2003-12-01 2011-03-28 液体因子ｖｉｉ組成物のウイルス濾過
JP2011178873A Withdrawn JP2012021007A (ja) 2003-12-01 2011-08-18 液体因子ｖｉｉ組成物のウイルス濾過

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2006541943A Expired - Lifetime JP4874806B2 (ja) 2003-12-01 2004-12-01 液体因子ｖｉｉ組成物のウイルス濾過
JP2011069695A Expired - Lifetime JP5666359B2 (ja) 2003-12-01 2011-03-28 液体因子ｖｉｉ組成物のウイルス濾過

Country Status (14)

Country Link
US (8) US20070142625A1 (https=)
EP (3) EP1711513B1 (https=)
JP (3) JP4874806B2 (https=)
KR (1) KR101234170B1 (https=)
CN (3) CN106916802B (https=)
AU (1) AU2004294403A1 (https=)
BR (1) BRPI0416950B8 (https=)
CA (1) CA2545474A1 (https=)
DK (1) DK1711513T3 (https=)
ES (2) ES2926359T3 (https=)
PL (1) PL1711513T3 (https=)
PT (1) PT1711513E (https=)
RU (1) RU2472804C2 (https=)
WO (1) WO2005054275A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1711513B1 (en) * 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration of factor vii solutions to remove virus
DE102005037824A1 (de) * 2005-08-08 2007-02-15 Zlb Behring Gmbh Neuartiges Virusreduktionsverfahren
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
ES2685079T3 (es) 2011-03-25 2018-10-05 F. Hoffmann-La Roche Ag Procedimientos de purificación de proteínas novedosos
DK3103861T3 (da) * 2012-06-21 2020-11-16 Baxalta GmbH Virusfiltrering af cellekulturmedier
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
RU2526494C1 (ru) * 2013-03-19 2014-08-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Челябинская государственная медицинская академия" Министерства здравоохранения Российской Федерации" (ГБОУ ВПО ЧелГМА Минздрава России) Способ удаления вируса иммунодефицита человека из спермы мужчины
MX380902B (es) * 2013-11-15 2025-03-12 Genentech Inc Métodos para la inactivación viral usando detergentes ecológico.
CN105435644A (zh) * 2014-09-29 2016-03-30 中国石油化工股份有限公司 一种纳滤膜及其制备方法
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
WO2021030787A1 (en) 2019-08-15 2021-02-18 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
US20230287335A1 (en) * 2020-07-30 2023-09-14 Amgen Inc. Cell culture media and methods of making and using the same
USD1013170S1 (en) 2020-10-29 2024-01-30 Cilag Gmbh International Surgical instrument assembly

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3100501A (en) 1960-12-23 1963-08-13 Crane Co Removable head and seat ball valve construction
JPS6033009B2 (ja) * 1978-12-29 1985-07-31 三菱電機株式会社 マイクロ波発振装置
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4540573A (en) * 1983-07-14 1985-09-10 New York Blood Center, Inc. Undenatured virus-free biologically active protein derivatives
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US5580560A (en) 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
EP1479395A1 (en) 1991-02-28 2004-11-24 Novo Nordisk A/S Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
DE4142908C2 (de) * 1991-12-24 1994-02-10 Octapharma Ag Glarus Verfahren zur Herstellung eines virusinaktivierten Prothrombinkomplex-Konzentrats (PPSB)
DK38293D0 (da) 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
SE9500724D0 (sv) 1994-06-23 1995-02-24 Pharmacia Ab Filtrering
US5677162A (en) * 1995-05-01 1997-10-14 New York Blood Center, Inc. Method for activating prothrombin to thrombin
AT406019B (de) * 1995-05-08 2000-01-25 Immuno Ag Verfahren zur herstellung eines arzneimittels enthaltend ein oder mehrere plasmaderivate
EP0860444A1 (en) 1997-02-24 1998-08-26 Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) Method for removing viruses from a protein solution
AT405608B (de) * 1997-04-08 1999-10-25 Immuno Ag Verfahren zur inaktivierung von pathogenen, insbesondere von viren, in einem biologischen material
AT407159B (de) * 1997-06-13 2001-01-25 Immuno Ag Verfahren zur abreicherung von viralen und molekularen pathogenen aus einem biologischen material
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
ATA159597A (de) * 1997-09-19 2000-09-15 Immuno Ag Präparat zur behandlung von blutgerinnungsstörungen
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6693075B1 (en) 1997-10-23 2004-02-17 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6017882A (en) 1997-10-23 2000-01-25 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US5981254A (en) 1997-10-30 1999-11-09 Haemacure Corporation Process for producing thrombin from plasma
WO1999022753A1 (fr) * 1997-11-05 1999-05-14 Yoshitomi Pharmaceutical Industries, Ltd. Preparations a base du cofacteur ii de l'heparine et procede de preparation
FI106465B (fi) 1998-06-10 2001-02-15 Suomen Punainen Risti Veripalv Menetelmä virusturvallisten farmaseuttisten koostumusten valmistamiseksi
AT408613B (de) 1998-06-17 2002-01-25 Immuno Ag Pharmazeutisches faktor vii-präparat
EP1198565A1 (en) 1999-07-07 2002-04-24 Maxygen Aps A method for preparing modified polypeptides
JP4451514B2 (ja) 1999-08-24 2010-04-14 財団法人化学及血清療法研究所 血液凝固第ｖｉｉ因子改変体
DE60138364D1 (de) 2000-02-11 2009-05-28 Bayer Healthcare Llc Gerinnungsfaktor vii oder viia konjugate
DE60143292D1 (de) 2000-05-03 2010-12-02 Novo Nordisk Healthcare Ag Varianten des menschlichen Koagulationsfaktors VII
DE10022092A1 (de) 2000-05-08 2001-11-15 Aventis Behring Gmbh Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
AU8755001A (en) 2000-09-13 2002-03-26 Novo Nordisk As Human coagulation factor vii variants
EP1325127B1 (en) 2000-10-02 2009-03-11 Novo Nordisk Health Care AG Method for the production of vitamin k-dependent proteins
AU2002218029A1 (en) 2000-11-09 2002-05-21 The Scripps Research Institute Modified factor viia
MXPA03008590A (es) 2001-03-22 2003-12-08 Novo Nordisk Healthcare Ag Derivados del factor vii de coagulacion.
BR0212818A (pt) 2001-09-27 2004-10-05 Novo Nordisk Healthcare Ag Polipeptìdeo de fator vii, construção de polionucletìdeo, célula hospedeira, animal transgênico, planta transgênica, método para produzir o polipeptìdeo de fator vii composição farmacêutica, uso de um polipeptìdeo de fator vii, e, método para o tratamento de distúrbios do sangramento em um sujeito ou para o aprimoramento do sistema hemostático normal
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
JP2005512524A (ja) 2001-11-02 2005-05-12 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ヒト凝固第ｖｉｉ因子ポリペプチド
DE10211632A1 (de) 2002-03-15 2003-10-09 Aventis Behring Gmbh Verfahren zur Abtrennung von Viren aus einer Proteinlösung durch Nanofiltration
SI1499719T1 (sl) 2002-04-30 2011-03-31 Bayer Healthcare Llc Polipeptidne variante faktorja VII ali VIIa
CA2484173A1 (en) 2002-04-30 2003-11-13 Merck & Co., Inc. 4-azasteroid derivatives as androgen receptor modulators
RS20050051A (sr) 2002-07-23 2007-06-04 Bio-Products & Bio Engineering Ag., Farmaceutski aktivni sastojak preparata i medikamenata koji sadrže trombin ili imaju mogućnost stvaranja trombina
DK1528930T3 (da) 2002-07-23 2009-08-03 Bio & Bio Licensing Sa Thrombindannelsesdygtige og thrombinholdige farmaceutiske præparater af virksomt stof samt lægemidler
AU2003266931B2 (en) 2002-09-30 2010-01-21 Bayer Healthcare Llc FVII or FVIIa variants having increased clotting activity
EP1644030B1 (en) * 2003-07-01 2009-10-28 Novo Nordisk Health Care AG Liquid, aqueous pharmaceutical composition of factor vii polypeptides
EP1711513B1 (en) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration of factor vii solutions to remove virus
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
FR2901796A1 (fr) 2006-05-31 2007-12-07 Lab Francais Du Fractionnement Procede d'extraction d'une ou de plusieurs proteines presentes dans du lait
FR2904558B1 (fr) 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
FR2910786B1 (fr) 2006-12-29 2017-08-11 Laboratoire Francais Du Fractionnement Et Des Biotechnologies (Lfb) "procede d'extraction d'une proteine presente dans du lait"
FR2947181B1 (fr) 2009-06-26 2012-05-04 Lfb Biotechnologies Composition de facteur vii
EP2687595B1 (en) 2012-07-19 2018-05-30 Laboratoire Français du Fractionnement et des Biotechnologies Method for purifying transgenic factor VII

Similar Documents

Publication Publication Date Title
JP2012021007A5 (https=)
JP2011506530A5 (https=)
JP2015520667A5 (https=)
JP2011508438A5 (https=)
JP2014517802A5 (https=)
JP2011525472A5 (https=)
JP2010518805A5 (https=)
JP2009537315A5 (https=)
JP2014138100A5 (https=)
WO2016126596A3 (en) Urea sequestration compositions and methods
JP2011170856A5 (https=)
JP2014530840A5 (https=)
CL2014001728A1 (es) Metodo para prevenir el crecimiento microbiano en membranas de filtracion durante el proceso de desalinizacion.
JP2010110202A5 (https=)
JP2016508542A5 (https=)
JP2015501646A5 (https=)
CL2014000425A1 (es) Sistema y metodo de purificacion de agua que comprende por lo menos dos medios de filtracion dimensionados de manera reciproca para permitir que un primer contaminante sature el primer medio y un segundo contaminante sature el segundo medio, y una membrana para filtrar agentes patogenos.
JP2013023736A5 (https=)
JP2013500200A5 (https=)
JP2013504386A5 (https=)
BR112013030851A2 (pt) sistema anti-incrustação de tratamento de água, meio de transformação na forma de uma composição granular de transformação, e, processo para preparar e usar um sistema anti-incrustação
HUE048958T2 (hu) Eljárás levegõnek nem kívánatos komponensektõl való megtisztítására és az ilyen komponensek eltávolítására, valamint az eljárás alkalmazása
JP2014518867A5 (https=)
EP2671860A4 (en) PROCESS FOR CLEANING 2,3,3,3-TETRAFLUORPROPES
CL2014001290A1 (es) Proceso para la recuperacion de betaina de melazas; producto de melaza de remolacha; y su uso.